Clofarabine Bone Marrow Cytoreduction

This study has been completed.
Sponsor:
Collaborator:
Genzyme, a Sanofi Company
Information provided by (Responsible Party):
University of Chicago
ClinicalTrials.gov Identifier:
NCT00724009
First received: July 25, 2008
Last updated: January 30, 2014
Last verified: January 2014

July 25, 2008
January 30, 2014
December 2007
September 2010   (final data collection date for primary outcome measure)
Cytoreductive Response [ Time Frame: Day 12 ] [ Designated as safety issue: No ]
Percent of patients achieving cytoreductive response of marrow cellularity <20% and blasts < 10%
66% of patients given clofarabine induction will achieve a cytoreductive response. [ Time Frame: Day 12 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT00724009 on ClinicalTrials.gov Archive Site
  • Number of Participants With Renal Adverse Events [ Time Frame: Day 12 ] [ Designated as safety issue: Yes ]
    Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
  • Number of Participants With Hepatic (Total Bilirubin) Adverse Events [ Time Frame: Day 12 ] [ Designated as safety issue: Yes ]
    Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
  • Number of Participants With Hepatic (SGOT) Adverse Events [ Time Frame: Day 12 ] [ Designated as safety issue: Yes ]
    Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
  • Number of Participants With Cardiac Adverse Events [ Time Frame: Day 12 ] [ Designated as safety issue: Yes ]
    Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
  • Number of Participants With Skin Adverse Events [ Time Frame: Day 12 ] [ Designated as safety issue: Yes ]
    Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
  • Number of Participants Infection Adverse Events [ Time Frame: Day 12 ] [ Designated as safety issue: Yes ]
    Treatment-related toxicity was calculated according to Common Terminology Criteria for Adverse Events (CTCAE) version 3.0.
  • Leukemia Free Survival [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Time to event analysis used the day of transplant as day 0.
leukemia free survival, treatment-related toxicity [ Time Frame: Day 100 ] [ Designated as safety issue: Yes ]
Not Provided
Not Provided
 
Clofarabine Bone Marrow Cytoreduction
Clofarabine Bone Marrow Cytoreduction : Feasibility of Induction as a Bridge to Allogeneic Stem Cell Transplantation for Patients With Relapsed or Refractory Acute Leukemias, Myelodysplastic Syndromes, and Advanced Myeloproliferative Diseases.

For relapsed and refractory leukemia patients induction chemotherapy prior to initiating a conditioning regimen will decrease residual leukemia (as measured by bone marrow leukemia blast percentage) at the time of HCT. This should lead to reduced relapse while still maintaining low transplant related mortality.

Screening will be done prior to enrollment in the study. The following will be done as part of the screening process:

  • Medical history review
  • Physical exam
  • Measurement of vital Signs
  • Blood tests (approximately 6 teaspoons of blood) will be done to see if the liver and kidneys are healthy, HIV (the virus that causes AIDS) test for this study and pregnancy test.
  • Urine test
  • Bone marrow biopsy and aspirate

If the patient is ineligible or does not have a donor for Allogeneic Stem Cell transplantation, you will not be able to participate in this clinical trial.

After results of these tests are obtained, your doctor will decide whether you can participate in this study.

Study procedures:

The study drug will be given for 5 days.

Days 1 through 5:

The patient will receive dexamethasone 1.5 hours prior to the administration of Clofarabine as part of standard care for subjects receiving Clofarabine.

The patient will receive an intravenous (IV) injection (into the vein) of Clofarabine each day for 5 days. This injection is given in the hospital and will be given over approximately 60 minutes each day. The actual dose of Clofarabine is based on the weight and height of the subject.

The patient will have the following tests done to see the effects of the study drug:

Each day of Clofarabine administration, on day 12 and then each day until stem cell transplantation:

  • Physical exam
  • Vital signs
  • Blood tests. About 3-4 teaspoons will be taken each time.

Day 12 after Clofarabine administration and then as outlined for stem cell transplantation:

• Bone marrow biopsy and aspirate.

After Clofarabine administration, there will be short resting period of 7-14 days. After the resting period, the patient will start receiving conditioning chemotherapy regimen (other standard of care drugs to better prepare your body for the stem cell transplant). This regimen will begin 15-21 days after they first received Clofarabine, and consists of additional treatment (chemotherapy and/or radiation). The type of treatment(s) the patient will receive for conditioning is dependent on the type of disease. In addition, this treatment will be decided by your doctor and is independent of this research. The duration of the conditioning period is variable and may take between 5-8 days. Stem cells are usually given one day after the completion of this regimen, which will be between 21 and 30 days after the patient has first received Clofarabine.

Follow-up Subjects who have a response and proceed with stem cell transplant will be followed weekly for the first three months and then every month for six months, then every two months for 12 months, then every three months for 18 months. The stem cell transplant will be done 21-30 days after first receiving Clofarabine. Subjects who do not go on to stem cell transplant will be followed for 3 months following administration of Clofarabine.

At these visits, the following will be done:

  • A physical exam
  • Medical history
  • Blood tests (about 3 teaspoons blood will be taken) performed.

End of study

At this time, the following tests will be done:

  • Physical exam
  • Blood tests
  • Bone marrow biopsy
Interventional
Phase 2
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Leukemia
Drug: Clofarabine
Clofarabine for injection should be diluted with 0.9% sodium chloride injection USP or European Pharmacopeia (EP) normal saline (NS) or 5% dextrose injection (D5W) USP or EP prior to IV infusion. The resulting admixture may be stored at room temperature, but must be used within 24 hours of preparation. Clofarabine should be diluted with NS or D5W prior to administering by IV infusion. The dosage is based on the patient's body surface area (BSA), calculated using the actual height and weight before the start of each cycle. To prevent drug incompatibilities, no other medications should be administered through the same IV line.
Other Name: Clolar
Experimental: Clofarabine
Clofarabine 30 mg/m2/day IV infusion over one hour for 5 consecutive days
Intervention: Drug: Clofarabine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
29
September 2012
September 2010   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Capable of understanding the investigational nature, potential risks and benefits of the study, and able to provide valid informed consent.
  • Adequate hepatobiliary function as indicated by the following laboratory values:

    • SGOT/SGPT <=2.5 x upper limit of normal
    • Alkaline phosphatase <=2.5 x upper limit of normal
    • Serum bilirubin < 1.5 mg/dl
    • Adequate renal function as indicated by the following laboratory values:
    • Creatinine Clearance >50 ml/min
  • Age >/=18 years
  • Zebroid performance status </= 2 (See Appendix A)
  • Life expectancy is not severely limited by concomitant illness (i.e. < 3months life expectancy from non-leukemic conditions).
  • No evidence of chronic active hepatitis or cirrhosis.
  • HIV-negative
  • Male and female patients must use an effective contraceptive method during the study and for a minimum of 6 months after study treatment.
  • Female patients of childbearing potential must have a negative serum pregnancy test within 2 weeks prior to enrollment.

Exclusion Criteria:

  • Current concomitant chemotherapy, radiation therapy, or immunotherapy other than as specified in the protocol.
  • Use of investigational agents within 30 days or any anticancer therapy within 2 weeks before study entry with the exception of hydroxyurea. The patient must have recovered from all acute non-hematologic toxicities from any previous .
  • Have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart, kidney, liver, or other organ system that may place the patient at undue risk to undergo treatment.
  • Patients with a systemic fungal, bacterial, viral, or other infection not controlled (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment).
  • Pregnant or lactating patients.
  • Any significant concurrent disease, illness, or psychiatric disorder that would compromise patient safety or compliance, interfere with consent, study participation, follow up, or interpretation of study results.
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
United States
 
NCT00724009
15809B
No
University of Chicago
University of Chicago
Genzyme, a Sanofi Company
Principal Investigator: Wendy Stock, MD University of Chicago
University of Chicago
January 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP